JP2013543489A - 新規ブロックコポリマーおよびミセル組成物ならびにその使用法 - Google Patents

新規ブロックコポリマーおよびミセル組成物ならびにその使用法 Download PDF

Info

Publication number
JP2013543489A
JP2013543489A JP2013530130A JP2013530130A JP2013543489A JP 2013543489 A JP2013543489 A JP 2013543489A JP 2013530130 A JP2013530130 A JP 2013530130A JP 2013530130 A JP2013530130 A JP 2013530130A JP 2013543489 A JP2013543489 A JP 2013543489A
Authority
JP
Japan
Prior art keywords
block copolymer
micelle
composition
copolymer according
pham
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013530130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543489A5 (enExample
Inventor
ジンミン ガオ
デービッド ブースマン
ケジン チョウ
シャオナン ホアン
イグアン ワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2013543489A publication Critical patent/JP2013543489A/ja
Publication of JP2013543489A5 publication Critical patent/JP2013543489A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0082—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion micelle, e.g. phospholipidic micelle and polymeric micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F299/00—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers
    • C08F299/02—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers from unsaturated polycondensates
    • C08F299/022—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers from unsaturated polycondensates from polycondensates with side or terminal unsaturations
    • C08F299/024—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers from unsaturated polycondensates from polycondensates with side or terminal unsaturations the unsaturation being in acrylic or methacrylic groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • C08G81/024—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G
    • C08G81/025—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G containing polyether sequences
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/01—Atom Transfer Radical Polymerization [ATRP] or reverse ATRP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Graft Or Block Polymers (AREA)
JP2013530130A 2010-09-22 2011-08-11 新規ブロックコポリマーおよびミセル組成物ならびにその使用法 Pending JP2013543489A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US38542210P 2010-09-22 2010-09-22
US61/385,422 2010-09-22
US201161470441P 2011-03-31 2011-03-31
US61/470,441 2011-03-31
US201161471054P 2011-04-01 2011-04-01
US61/471,054 2011-04-01
PCT/US2011/001418 WO2012039741A1 (en) 2010-09-22 2011-08-11 Novel block copolymer and micelle compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016175152A Division JP6471129B2 (ja) 2010-09-22 2016-09-08 新規ブロックコポリマーおよびミセル組成物ならびにその使用法

Publications (2)

Publication Number Publication Date
JP2013543489A true JP2013543489A (ja) 2013-12-05
JP2013543489A5 JP2013543489A5 (enExample) 2016-02-25

Family

ID=45874087

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013530130A Pending JP2013543489A (ja) 2010-09-22 2011-08-11 新規ブロックコポリマーおよびミセル組成物ならびにその使用法
JP2016175152A Active JP6471129B2 (ja) 2010-09-22 2016-09-08 新規ブロックコポリマーおよびミセル組成物ならびにその使用法
JP2019007460A Active JP6812471B2 (ja) 2010-09-22 2019-01-21 新規ブロックコポリマーおよびミセル組成物ならびにその使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016175152A Active JP6471129B2 (ja) 2010-09-22 2016-09-08 新規ブロックコポリマーおよびミセル組成物ならびにその使用法
JP2019007460A Active JP6812471B2 (ja) 2010-09-22 2019-01-21 新規ブロックコポリマーおよびミセル組成物ならびにその使用法

Country Status (7)

Country Link
US (10) US9631041B2 (enExample)
EP (3) EP2619238B1 (enExample)
JP (3) JP2013543489A (enExample)
AU (1) AU2011306076B2 (enExample)
CA (1) CA2811692C (enExample)
ES (1) ES2626437T3 (enExample)
WO (2) WO2012039741A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518145A (ja) * 2012-04-05 2015-06-25 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ｐＨ活性化型多色蛍光ナノプラットフォーム
JP2017526753A (ja) * 2014-06-06 2017-09-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ｐＨ応答性ポリマーのライブラリー及びそのナノプローブ
JP2019511483A (ja) * 2016-03-02 2019-04-25 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 免疫療法のためのｓｔｉｎｇ活性化ナノワクチン
JP2022502531A (ja) * 2018-10-12 2022-01-11 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイションUniversity of Pittsburgh − Of the Commonwealth System of Higher Education 薬剤を送達するための小型ポリマー担体
JP2022534497A (ja) * 2019-05-28 2022-08-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ｐＨ応答性組成物およびその使用法
JP2023500703A (ja) * 2019-11-04 2023-01-10 オンコナノ・メディスン・インコーポレイテッド ｐＨ応答性ブロックコポリマー組成物、ミセル、及び使用の方法
JP2024001088A (ja) * 2017-12-22 2024-01-09 ノース カロライナ ステート ユニバーシティ ポリマーフルオロフォア、それを含む組成物、ならびにその調製および使用方法

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2619331T (pt) 2010-09-22 2018-06-01 Univ Texas Métodos de tratamento de cancro incluindo rastreio de nqo1
EP2619238B1 (en) 2010-09-22 2017-03-08 The Board of Regents of the University of Texas System Novel block copolymer and micelle compositions and methods of use thereof
CN103215577B (zh) * 2012-05-07 2015-04-01 中国科学院苏州纳米技术与纳米仿生研究所 在金属表面制备具有pH响应性的高分子膜的方法
CN102942918A (zh) * 2012-11-08 2013-02-27 中国科学院化学研究所 一种聚甜菜碱荧光标记剂及其制备方法
JP6190534B2 (ja) 2013-08-22 2017-08-30 ソニー株式会社 水溶性蛍光染料又は有色染料及びその使用方法
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CN105813648A (zh) * 2013-09-17 2016-07-27 光明之火生物科学公司 氯毒素缀合物及其使用方法
EP3164111B1 (en) 2014-07-02 2019-04-03 The Research Foundation for the State University of New York Surfactant-stripped micelle compositions with high cargo to surfactant ratio
JP6806694B2 (ja) 2015-02-26 2021-01-06 ソニー株式会社 共役基を含む水溶性蛍光染料または有色染料
KR102773661B1 (ko) 2016-04-01 2025-02-27 소니그룹주식회사 초휘도 이량체성 또는 중합체성 염료
WO2017177065A2 (en) 2016-04-06 2017-10-12 Sony Corporation Ultra bright dimeric or polymeric dyes with spacing linker groups
WO2017181149A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
KR102526802B1 (ko) 2016-05-11 2023-05-02 소니그룹주식회사 초고명도 이량체성 또는 중합체성 염료
US12018159B2 (en) 2016-07-29 2024-06-25 Sony Group Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
CN106432647B (zh) * 2016-09-26 2018-10-30 华南理工大学 基于叔氨基的pH响应嵌段聚合物及其混合胶束与应用
US10188606B2 (en) * 2016-10-07 2019-01-29 Mayo Foundation For Medical Education And Research Expansile crosslinked polymersome for pH-sensitive delivery of anticancer drugs
WO2019071208A1 (en) 2017-10-05 2019-04-11 Sony Corporation PROGRAMMABLE POLYMERIC MEDICAMENTS
JP7403744B2 (ja) 2017-10-05 2023-12-25 ソニーグループ株式会社 プログラマブルな樹枝状薬物
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
KR102773157B1 (ko) * 2017-12-13 2025-02-27 소니그룹주식회사 생물학적 활성 화합물을 함유하는 이온성 중합체
JP2021510698A (ja) 2018-01-12 2021-04-30 ソニー株式会社 生物学的に活性な化合物を含むホスホアルキルリボースポリマー
EP3737418B1 (en) 2018-01-12 2024-02-28 Sony Group Corporation Polymers with rigid spacing groups comprising biologically active compounds
US11874280B2 (en) 2018-03-19 2024-01-16 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
WO2019182766A1 (en) 2018-03-21 2019-09-26 Sony Corporation Polymeric tandem dyes with linker groups
WO2019204799A1 (en) 2018-04-20 2019-10-24 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids
WO2020006285A1 (en) 2018-06-27 2020-01-02 Sony Corporation Polymeric dyes with linker groups comprising deoxyribose
CA3112319A1 (en) * 2018-09-15 2020-03-19 The Board Of Regents Of The University Of Texas System Dual modality ups nanoprobes for tumor acidosis imaging
CN109738402B (zh) * 2018-12-27 2022-05-27 南方医科大学 一种表面活性剂临界胶束浓度的荧光探针滴定法
CN110078948B (zh) * 2019-04-29 2021-09-24 西北师范大学 一种具有pH响应性陶罐状聚合物微球及其制备方法
WO2020247601A1 (en) * 2019-06-04 2020-12-10 Aravasc Inc. Polymeric micelle complexes, formulations, and uses thereof
KR102718543B1 (ko) 2019-09-26 2024-10-18 소니그룹주식회사 링커 그룹을 갖는 중합체성 탠덤 염료
CA3175449A1 (en) * 2020-04-15 2021-10-21 Christopher Winfried BARNER-KOWOLLIK Fluorescent macromolecule and uses thereof
US11786464B2 (en) 2020-04-24 2023-10-17 The Board Of Regents Of The University Of Texas System PH responsive block copolymer compositions and micelles that inhibit MCT 1 and related proteins
JP2023548341A (ja) * 2020-11-03 2023-11-16 オンコナノ・メディスン・インコーポレイテッド 治療用ｐＨ応答性組成物
EP4256078A1 (en) 2020-12-07 2023-10-11 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
US20250009656A1 (en) * 2021-11-15 2025-01-09 The Board Of Regents Of The University Of Texas System Ultra ph-sensitive micelles encapsulating cytokines for treatment of cancer
CN115785346B (zh) * 2022-01-20 2025-07-18 北京大学 含非pH敏感型单体的pH敏感聚合物的合成及应用
WO2024098064A2 (en) * 2022-11-06 2024-05-10 Onconano Medicine, Inc. Protonated ph responsive polymer encapsulation of bispecific antibodies and cytokines
CN116333190B (zh) * 2023-03-06 2024-05-24 郑州大学 一种多重响应的前药聚合物、制备方法和应用
CN116730969B (zh) * 2023-06-26 2024-04-19 中国药科大学 一种β-拉帕醌-氨基酸缀合物及其制备方法和应用
WO2025129124A1 (en) * 2023-12-15 2025-06-19 The Board Of Regents Of The University Of Texas System Stimuli-responsive sting-activating polymer compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074026A1 (en) * 2002-03-07 2003-09-12 Biocompatibles Uk Limited Drug carriers comprising amphiphilic block copolymers
US20080081075A1 (en) * 2006-10-02 2008-04-03 National Tsing Hua University Multifunctional mixed micelle of graft and block copolymers and preparation thereof
WO2009138473A2 (en) * 2008-05-15 2009-11-19 Biocompatibles Uk Limited Intracellular antibody delivery

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB475131A (en) 1935-05-16 1937-11-15 Du Pont Esters of acids of the acrylic series and their applications
GB1174148A (en) 1967-08-11 1969-12-10 Nii Monomerov Dlya Sint Kauchu Method of producing Acrylic and Methacrylic Esters
CS225516B1 (cs) 1982-07-29 1984-02-13 Vacik Jiri Způsob výroby béziekých esterů kyseliny methakrylové
US6660793B1 (en) 2000-06-15 2003-12-09 E. I. Du Pont De Nemours And Company Aqueous coating compositions having improved transparency
US6852816B2 (en) * 2000-10-06 2005-02-08 Biocompatibles Uk Limited Zwitterionic polymers
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
EP1340492A1 (en) 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
WO2005072752A1 (ja) * 2004-01-30 2005-08-11 Taisho Pharmaceutical Co., Ltd. 高リン血症の予防又は治療剤
US7812051B2 (en) * 2004-08-11 2010-10-12 Arqule, Inc. Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential
US7514400B2 (en) 2004-10-06 2009-04-07 The Penn State Research Foundation Synthetic mimics of mammalian cell surface receptors: method and compositions
WO2006078914A1 (en) * 2005-01-21 2006-07-27 Washington University In St. Louis Compounds having rd targeting motifs
WO2007067733A2 (en) 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Compositions and methods to monitor rna delivery to cells
US20080248097A1 (en) * 2007-02-26 2008-10-09 Kwon Glen S Polymeric micelles for combination drug delivery
JP2011503067A (ja) 2007-11-07 2011-01-27 マリンクロッド・インコーポレイテッド 生物学的適用のためのフォトニックシェルコアが架橋し、官能化されたナノ構造
FR2924432B1 (fr) 2007-11-30 2010-10-22 Cray Valley Sa Dispersion aqueuse de polymere structuree en coeur/ecorce, son procede de preparation et son application dans les revetements
EP2285853B1 (en) * 2008-05-13 2013-02-27 University of Washington Micellic assemblies
JP2011522616A (ja) 2008-06-04 2011-08-04 セブンス センス バイオシステムズ，インコーポレーテッド シングルステップ診断のための組成物および方法
EP2373715A4 (en) * 2008-12-08 2014-12-03 Univ Washington OMEGA FUNCTIONALIZED POLYMERS, TRANSITIONALIZED BLOCK COPOLYMERS, POLYMER BIOKON JUGATES, AND RADICAL CHAIN EXTENSION POLICY RESPONSE
WO2010116063A1 (fr) 2009-04-09 2010-10-14 L'oreal Copolymère éthylénique à motifs peg, cationique et anionique, composition cosmétique le comprenant et procédé de traitement
US20100303731A1 (en) 2009-05-29 2010-12-02 Searete Llc Systems, devices, methods, and compositions including selectively accessible ferromagnetic structures
US20120309691A1 (en) 2010-02-04 2012-12-06 Dapeng Zhou Tumor targeted delivery of immunomodulators by nanopolymers
EP2619238B1 (en) 2010-09-22 2017-03-08 The Board of Regents of the University of Texas System Novel block copolymer and micelle compositions and methods of use thereof
WO2012040513A1 (en) 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Compositions and methods for the delivery of beta lapachone
US9511152B2 (en) 2012-04-05 2016-12-06 The Board Of Regents Of The University Of Texas System Multicolored pH-activatable fluorescence nanoplatform
KR101405333B1 (ko) 2013-09-12 2014-06-11 유비머트리얼즈주식회사 연마 입자, 연마 슬러리 및 이를 이용한 반도체 소자의 제조 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074026A1 (en) * 2002-03-07 2003-09-12 Biocompatibles Uk Limited Drug carriers comprising amphiphilic block copolymers
US20080081075A1 (en) * 2006-10-02 2008-04-03 National Tsing Hua University Multifunctional mixed micelle of graft and block copolymers and preparation thereof
WO2009138473A2 (en) * 2008-05-15 2009-11-19 Biocompatibles Uk Limited Intracellular antibody delivery

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Bright fluorescent nanoparticles for developing potential optical imaging contrast agents.", NANOSCALE, vol. 2, no. 4, JPN6015027545, April 2010 (2010-04-01), pages 548 - 58, ISSN: 0003111469 *
"Specific Interactions Improve the Loading Capacity of Block Copolymer Micelles in Aqueous Media", LANGMUIR, vol. 23, no. 13, JPN6015027543, 2007, pages 6947 - 6955, ISSN: 0003111467 *
"Synthesis of Novel Folic Acid-Functionalized Biocompatible Block Copolymers by Atom Transfer Radical", BIOMACROMOLECULES, vol. 6, no. 2, JPN6015027544, 2005, pages 1085 - 1096, ISSN: 0003111468 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518145A (ja) * 2012-04-05 2015-06-25 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ｐＨ活性化型多色蛍光ナノプラットフォーム
JP2017526753A (ja) * 2014-06-06 2017-09-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ｐＨ応答性ポリマーのライブラリー及びそのナノプローブ
JP2019511483A (ja) * 2016-03-02 2019-04-25 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 免疫療法のためのｓｔｉｎｇ活性化ナノワクチン
JP2024001088A (ja) * 2017-12-22 2024-01-09 ノース カロライナ ステート ユニバーシティ ポリマーフルオロフォア、それを含む組成物、ならびにその調製および使用方法
JP2022502531A (ja) * 2018-10-12 2022-01-11 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイションUniversity of Pittsburgh − Of the Commonwealth System of Higher Education 薬剤を送達するための小型ポリマー担体
JP2022534497A (ja) * 2019-05-28 2022-08-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ｐＨ応答性組成物およびその使用法
JP2023500703A (ja) * 2019-11-04 2023-01-10 オンコナノ・メディスン・インコーポレイテッド ｐＨ応答性ブロックコポリマー組成物、ミセル、及び使用の方法

Also Published As

Publication number Publication date
EP3170846A1 (en) 2017-05-24
JP6471129B2 (ja) 2019-02-13
US20130331426A1 (en) 2013-12-12
US20230085899A1 (en) 2023-03-23
US9751970B2 (en) 2017-09-05
US10017598B2 (en) 2018-07-10
JP2019070160A (ja) 2019-05-09
US12091486B2 (en) 2024-09-17
US20200325265A1 (en) 2020-10-15
HK1251004A1 (en) 2019-01-18
US20200330383A1 (en) 2020-10-22
US20170320993A1 (en) 2017-11-09
JP6812471B2 (ja) 2021-01-13
US20200333350A1 (en) 2020-10-22
EP2619238A4 (en) 2014-03-26
US20180291134A1 (en) 2018-10-11
US11098150B2 (en) 2021-08-24
US20140023590A1 (en) 2014-01-23
ES2626437T3 (es) 2017-07-25
WO2012039855A1 (en) 2012-03-29
US9631041B2 (en) 2017-04-25
CA2811692C (en) 2020-02-18
WO2012039741A1 (en) 2012-03-29
CA2811692A1 (en) 2012-03-29
US20160220706A1 (en) 2016-08-04
EP3345944B1 (en) 2020-03-18
EP2619238A1 (en) 2013-07-31
AU2011306076B2 (en) 2015-05-07
US20210198410A1 (en) 2021-07-01
JP2017061678A (ja) 2017-03-30
EP2619238B1 (en) 2017-03-08
AU2011306076A1 (en) 2013-04-04
EP3345944A1 (en) 2018-07-11

Similar Documents

Publication Publication Date Title
JP6471129B2 (ja) 新規ブロックコポリマーおよびミセル組成物ならびにその使用法
JP6234432B2 (ja) ｐＨ活性化型多色蛍光ナノプラットフォーム
Tian et al. Dextran-doxorubicin prodrug nanoparticles conjugated with CD147 monoclonal antibody for targeted drug delivery in hepatoma therapy
AU2015203892B2 (en) Novel block copolymer and micelle compositions and methods of use thereof
AU2016203456B2 (en) Novel block copolymer and micelle compositions and methods of use thereof
HK1251004B (en) Novel block copolymer and micelle compositions and methods of use thereof
HK1206613B (zh) 多色的ph可激活的荧光纳米平台

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140807

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160106

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160516